IPO Year: n/a
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
15-12G - Cellular Biomedicine Group, Inc. (0001378624) (Filer)
EFFECT - Cellular Biomedicine Group, Inc. (0001378624) (Filer)
EFFECT - Cellular Biomedicine Group, Inc. (0001378624) (Filer)
EFFECT - Cellular Biomedicine Group, Inc. (0001378624) (Filer)
EFFECT - Cellular Biomedicine Group, Inc. (0001378624) (Filer)
25-NSE - Cellular Biomedicine Group, Inc. (0001378624) (Subject)
S-8 POS - Cellular Biomedicine Group, Inc. (0001378624) (Filer)
POS AM - Cellular Biomedicine Group, Inc. (0001378624) (Filer)
POS AM - Cellular Biomedicine Group, Inc. (0001378624) (Filer)
POS AM - Cellular Biomedicine Group, Inc. (0001378624) (Filer)
This live feed shows all institutional transactions in real time.
SC 13D/A - Cellular Biomedicine Group, Inc. (0001378624) (Subject)
SC 13D/A - Cellular Biomedicine Group, Inc. (0001378624) (Subject)
Fastest customizable press release news feed in the world
ROCKVILLE, Md. and SHANGHAI, Feb. 19, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") today announced the completion of the merger (the "Merger") of the Company with CBMG Merger Sub Inc., a Delaware corporation ("Merger Sub") and a wholly-owned subsidiary of CBMG Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), pursuant to the previously announced Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 11, 2020, by and among the Company, Parent and Merger Sub. Under the terms of the Merger Agreement, which was approved by the Company's stockholders at its special
ROCKVILLE, Md. and SHANGHAI, Jan. 28, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company," "CBMG," "we" or "our"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that leading proxy advisory firms Glass, Lewis & Co. and Institutional Shareholder Services Inc. have both recommended that the Company's stockholders vote FOR the proposal to adopt the definitive merger agreement that provides for the acquisition of CBMG for $19.75 in cash per share of common stock in a going private transaction (the "merger proposal"). The Company will hold a special meeting o
GAITHERSBURG, Md. and SHANGHAI, Dec. 4, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that three abstracts relating to its immuno-oncology drug development have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held as a virtual event on December 5-8, 2020. C-CAR088Abstract Title: An Anti-BCMA CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple MyelomaProgram: Oral and
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)
4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)
4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)
4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)
4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)
4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)
4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)
4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)
4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)